Clinical Outcomes in Concurrent Cohorts of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA)-Treated versus ELX/TEZ/IVA-Ineligible Individuals with Cystic Fibrosis in the US during COVID-19
Abstract Introduction The initial US launch of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) coincided with the coronavirus disease 2019 (COVID-19) pandemic, altering healthcare-seeking behaviors and possibly resulting in decreased respiratory infection transmission. We evaluated real-world effecti...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Adis, Springer Healthcare
2026-05-01
|
| Seri Bilgileri: | Pulmonary Therapy |
| Konular: | |
| Online Erişim: | https://doi.org/10.1007/s41030-026-00363-0 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|